Inobaseru
504A.TTSE GROWTHPharmaceutical
Filed as Innovacell Inc. (2026-03–2026-08)
Financials · Consolidated
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 |
|---|---|---|---|
| Operating income | −¥2.2bn | −¥1.9bn | — |
| Ordinary income | −¥2.9bn | −¥2.4bn | −¥2.0bn |
| Net income (owners) | −¥2.9bn | −¥2.4bn | −¥2.0bn |
| Total assets | ¥5.1bn | ¥2.8bn | ¥2.4bn |
| Net assets / equity | −¥630m | −¥2.0bn | −¥1.7bn |
| Operating cash flow | −¥2.0bn | −¥1.3bn | −¥1.4bn |
| EPS (basic) | ¥-89 | ¥-89.42 | ¥-75.39 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 60 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 140 figures · EDINET |